Patents by Inventor Jeanne MAGRAM

Jeanne MAGRAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
    Publication number: 20210253691
    Abstract: Described herein are methods of selecting and treating patients likely to respond to treatment with an anti-LIF antibody.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 19, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Robin Matthew HALLETT, Peter Edward BAYLISS, Ajitha JEGANATHAN, Patricia Anne GIBLIN, Isabel Huber RUANO, Jeanne MAGRAM, Monica Pascual GARCIA, Ester Bonfill TEIXIDOR, Ester Planas RIGOL
  • COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
    Publication number: 20210187106
    Abstract: Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and platinum-based antineoplastic agents.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Robin Matthew HALLETT, Patricia Anne GIBLIN, Jeanne MAGRAM, Naimish PANDYA, Robert WASSERMAN, Angus SINCLAIR
  • Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
    Publication number: 20110311553
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE
  • Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
    Publication number: 20100119506
    Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
    Type: Application
    Filed: July 30, 2009
    Publication date: May 13, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Tobias LITZENBURGER, Sandra MILLER, Catrin PRACHT, Rainer BOXHAMMER, Jeanne MAGRAM, Patricia GIBLIN, Daniel RAJOTTE